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Abstract
By the use of high-throughput molecular technologies,
the number of genes and proteins potentially relevant
to testicular germ cell tumor (TGCT) and other
diseases will increase rapidly. In a recent transcrip-
tional profiling, we demonstrated the overexpression
of GRB7 and JUP in TGCTs, and confirmed the
reported overexpression of CCND2. We also have
recent evidences for frequent genetic alterations of
FHIT and epigenetic alterations of MGMT. To evaluate
whether the expression of these genes is related to
any clinicopathological variables, we constructed a
tissue microarray with 510 testicular tissue cores from
279 patients diagnosed with TGCT, covering various
histological subgroups and clinical stages. By immu-
nohistochemistry, we found that JUP, GRB7, and
CCND2 proteins were rarely present in normal testis,
but frequently expressed at high levels in TGCT.
Additionally, all premalignant intratubular germ cell
neoplasias were JUP-immunopositive. MGMT and
FHIT were expressed by normal testicular tissues,
but at significantly lower frequencies in TGCT. Except
for CCND2, the expressions of all markers were
significantly associated with various TGCT subtypes.
In summary, we have developed a high-throughput
tool for the evaluation of TGCT markers, and utilized
this to validate five candidate genes whose protein
expressions were indeed deregulated in TGCT.
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Introduction
Testicular germ cell tumors (TGCTs) of adolescent and
young adult males are classified into two main histological
subtypes, seminomas and nonseminomas [1], and both
types develop from premalignant intratubular germ cell
neoplasia unclassified (ITGCN; other used terms for these
lesions are carcinoma in situ, gonocytoma in situ, intra-
tubular malignant germ cell, and testicular intraepithelial
neoplasia) [2]. Whereas the seminomas resemble ITGCN cells,
but do not constrain within the tubules and are quite prolifera-
tive, the nonseminomas develop through a pluripotent embry-
onal carcinoma stage, which may differentiate into cells and
tissue types of all three primary germ layers at various stages
of differentiation (somatically differentiated teratomas and
extraembryonally differentiated choriocarcinomas and yolk
sac tumors). Thus, tumor development in the testis mimics
embryogenesis and makes TGCT an interesting model also for
developmental biology.
TGCT genomes are usually hypotriploid or hypertriploid with
extensive chromosome losses and gains [3]. Virtually all
TGCTs have extra copies of chromosome arm 12p, often seen
as an isochromosome [4–6]. There are also other chromo-
somal copy number alterations occurring at high frequencies,
implying the existence of genes within them with relevance to
TGCT development. Furthermore, epigenetically deregulated
gene expression through aberrant CpG island methylation
seems to be common in TGCTs [7].
In three recent reports on the genetics and epigenetics of
TGCT, we have gained evidence for specific genes involved in
the development of TGCT [8–10]. A cDNA microarray study,
mainly focusing on the frequently overrepresented chromo-
some arm 17q [11], revealed growth factor receptor-bound
protein 7 (GRB7) and junction plakoglobin (JUP; g-catenin)
as transcriptionally overexpressed in TGCT [8]. This study also
confirmed the overexpression of cyclin D2 (CCND2) [12–15].
By a candidate gene approach, we found epigenetic alterations
of the DNA repair gene O6-methylguanine-DNA methyltrans-
ferase (MGMT) and frequent allelic imbalances in the chromo-
some band 10q26 that harbors this gene [9]. Although in a
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limited series, methylation of theMGMT promoter was found
to be associated with lack of protein expression [9]. Further-
more, we reported the fragile histidine triad (FHIT) gene,
located within the commonly deleted region on 3p14, to have
aberrant splice variants and downregulated expression in
TGCT [10].
All these studies reported novel genes relevant to the
development of TGCT, but because of limited sample sizes
(range 14–70 TGCTs), only a few conclusions could be
drawn in relation to clinicopathological variables.
Tissue microarrays facilitate the validation of candidate
genes/proteins as a larger series of samples is evaluated,
and thus give statistically strong data to associations be-
tween genotypes or phenotypes and clinicopathological var-
iables [16–18]. We therefore constructed a tissuemicroarray
from archival blocks of a large series of primary TGCTs of
various clinical stages, including all histological subtypes, as
well as ITGCN and normal testicular tissues. We have
evaluated the in situ protein expressions of the candidates
JUP, GRB7, CCND2, MGMT, and FHIT in this set of testic-
ular tissue samples and correlated the results with clinical
and pathological variables.
Materials and Methods
Tumor Material and the Tissue Microarray Technology
A tissue microarray block was constructed with 510
testicular tissue cores punched from formalin-fixed and
paraffin-embedded tissue blocks from 279 individuals (278
orchiectomy specimens from TGCT patients and one testic-
ular autopsy from a person with no known history of cancer).
The distribution of histological subtypes is shown in Table 1.
One to five tissue cores of different histological subtypes
from each TGCT/patient were transferred into the array
block, reflecting the number of histological components. Fifty
of the tissue cores were replicates of the same histological
subtype taken from a different site of the same tumor, and
were included for validation of heterogeneity and consisten-
cy of staining. According to the Royal Marsden Staging
System (stage I: nonmetastatic TGCT; stages II– IV: meta-
static TGCT) [19], there were 174 patients classified as stage
I, 53 as stage II, 13 as stage III, and 38 as stage IV. Patients
without clinically demonstrated metastases underwent retro-
peritoneal lymph node dissection, or followed a surveillance
program. Patients with metastases received cisplatin-based
chemotherapy followed, in the majority of cases, by resection
of residual masses. The patients underwent orchiectomy
between 1981 and 1999, and all patients were followed up
until death or May 2002. All TGCT samples are available
from the archives of the Department of Pathology of The
Norwegian Radium Hospital. The study was approved by the
Regional Committee for Medical Research Ethics (S-00201,
150800).
Sections of up to 10 tissue blocks from each orchiectomy
specimen were stained with hematoxylin and eosin, and light
microscopically examined by an expert pathologist on germ
cell tumors (V.A.). The best areas for tissue punching were
marked. The tissue microarray was assembled using a
robotic tissue microarrayer. Briefly, cylindrical tissue cores
with 0.6 mm diameter were transferred from the donor
archival tissue blocks and arrayed into an empty recipient
paraffin block, building up the tissue microarray block [16].
The Instrumedics (Instrumedics, Hackensack, NJ) tape
transfer method was used to transfer 4-mm sections of the
tissue microarray block to glass slides. Hematoxylin and
eosin–stained tissue microarray sections were evaluated
to check for consistency with the originally assigned histol-
ogy. Histological classification was performed according to
World Health Organization recommendations [1]. The dis-
tinction of ITGCN from normal tissue was assisted by immu-
nohistochemical staining of a parallel section using
antibodies targeting germ cell and placental alkaline phos-
phatases (PLAP) extensively present in ITGCN but not in
normal spermatogenic germ cells [2,20].
Immunohistochemistry
Tissue microarray sections were stained with the biotin–
streptavidin peroxidase method (Supersensitive Immunode-
tection System, LP000-UL; BioGenex, San Raman, CA) and
OptiMax Plus Automated Cell Staining System (BioGenex).
One tissue microarray section for each antibody was depar-
affinized and rehydrated, and high-temperature antigen re-
trieval was performed by microwave oven at 900 W. The
slides were then incubated with 1% hydrogen peroxide
(H2O2) for 10 minutes to block endogenous peroxidase
activity before incubation with polyclonal antibodies GRB7
(N-20, sc-607, 1:100, 2 mg/ml IgG; Santa Cruz Biotechnolo-
gy, Inc., Santa Cruz, CA), CCND2 (C-17, sc-181, 1: 400, 0.5
mg/ml IgG; Santa Cruz Biotechnology, Inc.), MGMT (C-20,
sc-8825, 1:200, 1 mg/ml IgG; Santa Cruz Biotechnology,
Inc.), FHIT (ZP54, 1:100, 5 mg/ml IgG; Zymed Laboratories,
Inc., South San Francisco, CA), and monoclonal antibodies
JUP (clone 15, 1:300, 0.8 mg/ml IgG2a; Nota Bene Scientific
ApS, Hellebæk, Denmark) and PLAP (clone 8A9, 1:20,
IgG1k; Novocastra Laboratories Ltd., Newcastle, UK) for
30 minutes at room temperature. Afterward, the sections
were incubated for 20 minutes with multilink biotinylated anti-
immunoglobulins (1:30; BioGenex) and for 20 minutes with
streptavidin peroxidase (1:30; BioGenex). Finally, the sec-
tions were stained for 5 minutes with 0.05% of the peroxi-
dase substrate 3V3-diaminobenzidine tetrahydrochloride
Table 1. Histological Subtypes of 510 Testicular Tissue Cores in the Tissue
Microarray.
Histology Individuals (n) Tissue Cores (n)
Normal testis 22 28
Intratubular germ cell neoplasia 21 21
Seminoma 167 184
Embryonal carcinoma 99 102
Choriocarcinoma 16 16
Yolk sac tumor 62 69
Teratoma 75 90
Total 279* 510
*The total number of individuals is lower than the sum of each histological
subtype as there often are tissue cores of several histological subtypes
provided from each orchiectomy specimen.
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(DAB) freshly prepared in 0.05 M Tris–HCl buffer at pH=7.6
containing 0.01% H2O2, before being counterstained with
hematoxylin, dehydrated, and mounted.
Immunohistochemistry Scoring
For scoring the immunohistochemical staining, we used a
binary scoring of only ‘‘positive’’ and ‘‘negative’’ categories to
avoid making pseudoquantitative measures of individual
tissue cores. Upon deciding the cutoff criteria for individual
antibodies, we considered both general consensus for im-
munohistochemistry scoring and previously published scor-
ing systems.
JUP immunostaining was membranous and/or cytoplas-
mic (Figure 1). Cases with any membranous and/or moder-
ate to strong cytoplasmic staining were scored as positive.
GRB7 immunostaining was membranous and/or cytoplas-
mic. Cases with moderate or strong staining in the relevant
cells were scored as positive. CCND2 immunostaining was
nuclear, although some cytoplasmic staining was seen in
negative normal testicular tissues. Cases with staining of
more than 5% of the relevant nuclei were considered posi-
tive. MGMT immunostaining was nuclear, and cases with
staining of more than 5% of the relevant nuclei were consid-
ered positive. FHIT immunostaining was cytoplasmic and the
cases were evaluated according to the previously published
scoring system for FHIT immunohistochemistry [10,21]. This
system uses a composite score, which is calculated by
multiplication of the intensity (1, weak/absent; 2, moderate;
3, strong) and the fraction of positive cells (1, <10%; 2, 10–
50%; 3, >50%), where cases with composite scores of four or
above were regarded as FHIT-positive.
A tumor was considered positive when one or more of the
tumor tissue cores from that specific tumor were positive.
Equally, when more than one tissue core of a specific
histological component of a tumor was present on the array,
that specific component was considered positive if at least
one of the samples was scored as positive.
Control Experiments
All antibodies were purchased from commercial compa-
nies (see above), which have experimental evidence for their
specificity and detection of correct-sized proteins. We hy-
bridized each of the antibodies to a Western blot with cell
extracts from a panel of 17 cell lines cultured from various
types of tumor. Briefly, from each cell line, 25 mg of total
protein lysate was separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis and transferred onto
Immobilin P-membranes (Millipore, Bedford, MA). The mem-
brane was blocked and incubated with various antibodies
overnight at 4jC according to the recommendations of the
manufacturers. After washing, the immunoreactive proteins
were visualized using horseradish peroxidase–conjugated
secondary antibodies and the ECL Western blotting detec-
tion system (Amersham-Pharmacia Biotech, Amersham,
UK). Bands at correct sizes were detected for all five anti-
bodies, but additional bands at lower intensities and un-
known origin were seen for the antibodies against CCND2
and MGMT.
For three of the antibodies (GRB7, CCND2, and MGMT),
peptide antigenes were also available (Santa Cruz Biotech-
nology, Inc.), and we performed peptide blocking reactions
on separate tissue microarray sections. Furthermore, we
performed negative controls of all antibodies by replacement
of primary polyclonal antibodies with normal rabbit IgG at the
same concentration as the polyclonal antibodies and by
replacement of primary monoclonal antibodies with mouse
myeloma proteins of the same subclass and concentration
as the monoclonal antibodies. Both the peptide blocking and
the antibody replacement reactions gave satisfactory results.
Furthermore, test tissue microarrays containing 73 tissue
cores with normal and malignant tissues from 10 different
organs were used for the optimization of immunohistochem-
istry conditions, and this served as additional positive and
negative controls because the expressions of the five pro-
teins were known beforehand for several of the tissue types.
Statistical Analysis
Comparisons of different groups were statistically tested
with two-sided Fisher’s exact tests.
Results
In total, the immunohistochemical analyses of JUP, GRB7,
CCND2, MGMT, and FHIT resulted in 433, 414, 428, 434,
and 418 scored testicular tissue cores, from 256, 254, 260,
261, and 255 individuals, respectively. The frequencies of
positive staining for each antibody and histological subtype
are shown in Figure 1.
The frequencies of positive tissues according to histolog-
ical subtypes are illustrated in Figure 2A. For JUP, only 13%
of the normal tissues stained positive, compared to 100%
and 94% for ITGCN and seminomas (P = 1 105 and P = 1
 1010, respectively). The frequency of JUP-positives in
nonseminomas was 77%, which is significantly lower than
that for ITGCN and seminomas (Figure 2B; P = 6 104 and
P = 6  106, respectively).
For GRB7, 19% of the normals were scored positive,
compared to 55% of the ITGCN and 56% of the TGCTs
(P = .04 and P = 4  103, respectively). The frequency of
GRB7 immunoreactivity in seminomas (42%)was significant-
ly different from that in nonseminomas (66%; P = 1  104).
For CCND2, all normal tissues were negative, whereas
16% of the ITGCN samples and 55% of the TGCTs were
positive (P = 2  106; normal to invasive tumor). The
frequency of CCND2 immunoreactivity was similar in semi-
nomas and nonseminomas (P = 1.00).
For MGMT, all normal tissues had positive spermatogenic
cells, whereas the percentages of positives among ITGCN,
seminomas, and embryonal carcinomas were 47%, 16%,
and 6%, respectively (P = 6  105, 1  1013, and 8 
1017 when compared to normal testicular tissues). Howev-
er, among yolk sac tumors and teratomas, 49% and 44%
were positive, respectively, which signifies a significant
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reexpression of MGMT upon differentiation from embryonal
carcinoma (P = 4  109 and P = 2  107).
For FHIT, all normal tissues and 76% of ITGCN were
positive. Both seminomas (41%) and embryonal carcinomas
(38%) were positive in significantly fewer cases than both
normal tissues (P = 3  106 and P = 2  106) and ITGCN
(P = 9  103 and P = 6  103).
When we compared pure seminomas with the seminoma
components from combined tumors, no significant differ-
ences were seen in the expression patterns of the five
Figure 1. TGCT tissue microarray, immunohistochemical staining. For each of the five analyzed proteins, representative tissue cores of one normal testicular
parenchyma, one negative neoplasm, and one positive neoplasm are shown. The colored squares designate the histological subtype of each sample specified by
the color code of the histograms. The histograms, again, indicate the frequencies of positive cases for each histological subtype. N=normal spermatocytic germ
cells; I = intratubular germ cell neoplasia unclassified (carcinoma in situ); S = seminoma; E = embryonal carcinoma; C = choriocarcinoma; Y = yolk sac tumor; T =
teratoma.
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analyzed proteins (Figure 2B). The various antibodies also
revealed comparable staining in ITGCN samples from semi-
nomas and nonseminomas (Figure 2C). Within the terato-
mas, the epithelial components were significantly more
frequently positive for JUP and GRB7 than the mesenchymal
components (Figure 2D).
None of the markers was significantly associated with
clinical stage or mortality (Figure 2, E and F ). Among
TGCTs from patients with history of undescended testis
(cryptorchidism; Figure 2G), 40% were positive for CCND2,
as compared to 60% among TGCTs from patients with no
history of cryptorchidism (P = .03).
The immunostaining results evaluated for several combi-
nations (Figure 2H ) and the strongest associations were
seen between FHIT-positives and tumors positive for GRB7
and MGMT (P = 6  108 and P = 3  104), followed by
associations between CCND2-positives and tumors positive
for MGMT and GRB7 (P = .002 and P = .006).
Figure 2. Expression profiles of five TGCT candidate genes according to various clinical and pathological subgroups. The 510 testicular tissue cores, derived from
healthy and tumor tissues of 279 individuals, were subgrouped according to several criteria. Each row represents one subgroup of TGCT, and the colored squares
illustrate the frequencies of immunopositive cases for the different markers. Parenthesized numbers specify the number of analyzable tumors/patients from each
subgroup. The frequencies of immunopositive cases are summarized according to (A) the histological subgroup, (B) seminoma versus nonseminoma, (C)
intratubular germ cell neoplasia in proximity of seminoma versus nonseminoma, (D) the teratoma component, (E) clinical stage, (F) mortality, and (G) history of
undescended testis. Panel (H) presents the associations between the tested markers. Panel (I) presents the color code for the frequencies of immunopositive cases.
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Replicate tissue cores (i.e., same histological subtypes
from same tumors) were scored identically in 77% of the
cases [range 71% (for FHIT) to 80% (for GRB7)].
Discussion
As the human genome gets unraveled and high-throughput
molecular technologies are utilized, the number of genes with
putative relation to various diseases, including TGCT,
increases dramatically [3]. Hence, there is a need for valida-
tion of new putative disease markers, but so far, studies on
TGCT have analyzed too few samples to really pinpoint
significant associations to clinicopathological variables.
By the present study, we have taken advantage of the
tissue microarray technology [16–18], and by transferring
more than 500 cylindrical testicular tissue cores into a single
recipient block, we developed a tool enabling us to analyze
candidate testicular cancer genes in a large series of sam-
ples of all histological subtypes and stages, linked to a
database with relevant clinical, pathological, and genetic
information. We have used this tool to examine the protein
expression of five TGCT candidate genes. Four of these
(JUP,GRB7,MGMT, and FHIT) were recently targeted by us
[8–10], and the fifth is the CCND2 candidate gene on
chromosome arm 12p [8,12–15].
JUP and GRB7 showed high expression in TGCT but not
in normal testicular tissues in a cDNA microarray study
focusing on chromosome arm 17q [8], which is overrepre-
sented in every second TGCT [11]. By transcriptional profil-
ing using DNA microarrays, many genes are usually
analyzed in a relatively small sample set, often identifying a
molecular signature of the tumor in question, but with weak
statistics regarding the individual genes. However, by ana-
lyzing the two candidate genes JUP andGRB7 further on the
TGCT tissue microarray, we are confident about their gen-
eral overexpression in TGCT and also on their protein levels,
and evidence was provided for their differential expression
across various histological subtypes of TGCT.
JUP belongs to the catenin family and may have onco-
genic potential through its function in the WNT signaling
pathway [22,23]. Tissue microarray data demonstrated that
JUP protein is rarely expressed in normal spermatogenic
germ cells, even though it is expressed in virtually all ITGCN
and seminomas, and in most nonseminomas. However, it
remains to be elucidated whether the induction of JUP
expression is an initial event in the development of ITGCN,
or if JUP is already expressed in fetal gonocytes, the germ
cell precursors of which ITGCN is believed to originate from
[2,24]. The fact that the WNT pathway is involved in em-
bryogenesis, which again is mimicked by testicular tumori-
genesis, makes components of this pathway interesting
candidates for examination. The JUP binding partner E-
cadherin is expressed in embryonal carcinomas [25,26]
and the JUP homolog b-catenin is expressed in both normal
and malignant testicular tissues [26], but the impact of WNT
signaling in TGCT remains poorly understood.
GRB7 encodes an adaptor protein that, through its SH2
domain, interacts with the cytoplasmic domain of several
tyrosine kinase growth factor receptors, including ERBB2,
KIT, PDGFR, RET, and INSR [27–31], as well as with
cytoplasmic tyrosine kinases [32,33]. GRB7 also has a
RAS-associating– like domain [34] and plays a role in cell
migration [35,36]. Tissue microarray results for GRB7 con-
firm that positive immunostaining is more frequent in ITGCN,
seminomas, and nonseminomas than in normal testicular
tissues, but with the highest frequency in nonseminomas.
But still, seminoma components within combined TGCTs
were not more often positive than pure seminomas. Within
teratomas, epithelial parts were generally positive, whereas
mesenchymal components were not. In breast, esophageal,
and gastric cancers, GRB7 is often coamplified and co-
overexpressed with ERBB2 [27,37–39]. Although we do
not have copy number data for these two genes, the com-
bined CGH and cDNAmicroarray analyses of TGCT showed
that this chromosome region is overrepresented [11] but with
overexpression only of GRB7 [8], suggesting that the GRB7
protein interacts with another main target other than ERBB2
in these cells.
CCND2 is located at chromosome arm 12p, and several
studies have noted its high expression in TGCT [8,12–15].
This most likely reflects DNA sequence copy number gains
seen in virtually all TGCTs, and often as i(12p) [4,6,40].
However, CCND2 can also be induced downstream of
several molecular pathways such as RAS and WNT sig-
naling [41,42]. We noted that 56% of the TGCTs in our
series was immunopositive for CCND2, which is somewhat
lower than the frequency found by Bartkova et al. [14] (n =
31, 81%). In ITGCN, the frequency of CCND2-positives
was intermediate between the always-negative normals
and the TGCT samples. One might speculate whether
we underestimate the frequency of CCND2-positives in
ITGCN, as there are fewer ITGCN nuclei in each tissue
core than, for instance, seminoma nuclei in a seminoma
tissue core. However, as parallel sections were stained
with antibodies against germ cell and placental alkaline
phosphatases extensively present in ITGCN but absent in
normal spermatogenic germ cells, we saw that there were
usually about 50 intratubular malignant germ cells in each
ITGCN tissue core. Among the invasive tumors, we con-
firmed that the CCND2 expression is not associated with
histological subtype (P = 1.0), which has been previously
reported for the mRNA level [15]. CCND2 mRNA expres-
sion has been shown to correlate with the mRNA expres-
sion of its protein binding partner CDK4 [15] and, in the
present study, we demonstrated that its protein expression
correlated to those of GRB7 and MGMT. Interestingly, we
found in our series that TGCTs of patients with history of
cryptorchidism had a lower frequency of CCND2 immuno-
reactivity. However, this association is of borderline statis-
tical significance, and a biological impact would be an
enigma.
MGMT is a DNA repair gene, which was recently
demonstrated to be frequently inactivated in TGCTs by
promoter hypermethylation [9,43,44]. In the present study,
we have shown also that the amount of protein product is
downregulated, in particular in seminomas and embryonal
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Neoplasia . Vol. 5, No. 5, 2003
carcinomas. However, the MGMT protein seems to be
re-expressed upon further differentiation of embryonal car-
cinoma into choriocarcinomas, yolk sac tumors, and ter-
atomas. The observed hypermethylation of the MGMT
promoter fits well with such a reversible silencing mecha-
nism. The existence of other regulatory mechanisms for
MGMT expression is also evident, as the expression is lost
in most seminomas, a subgroup that, only infrequently, is
methylated in the MGMT promoter.
FHIT was also newly identified as relevant to TGCT
development [10]. We confirmed that the FHIT protein is
downregulated in half of the TGCTs compared to normal
testicular tissues. The downregulation seems to take place
when ITGCN is transformed into invasive TGCT (P = .009).
The immunoreactivity of FHIT was strongly associated with
those of GRB7 and MGMT. However, here we have failed to
confirm the associations proposed by the initial study [10]
between reduced FHIT expression and metastasis (present
study, P = .8) and that mesenchymal components of terato-
mas have more frequently reduced expression compared to
epithelial components (present study, P = .5). Ten whole
mount sections of TGCTs that also were present on the
tissue microarray were analyzed for FHIT staining, yielding
the same score in 8 of 10 cases. Hence, it is likely that the
conflicting conclusions of this and the previous FHIT study
were not due to the different technologies, but rather due to
the limited sample size and borderline significance levels of
the initial study.
For all tested markers, the frequencies of immunoreactive
cases were similar for pure seminomas and seminoma
components of combined TGCTs. Thus, this gives evidence
for seminomas of both groups to be evaluated together in the
same category in molecular studies of TGCT. Additionally,
this speaks in favor of seminomas developing through the
same molecular–pathological pathway, irrespective of
whether it is pure or in combination with nonseminoma
components.
The tissue microarray technology has been criticized
because the analysis of a small tissue core is not able to
reflect the situation of a larger heterogeneous tumor. We
therefore included 50 replicate tissue punches with identical
histology but from a different site in the tumor. Duplicate
tissue cores were scored differently in as much as 24% of the
cases (average of the five antibodies; data not shown). This
underlines the fact that tissue microarrays are not a tool for
the diagnosis of individual tumors, but because of the
possibility to analyze huge sample sets, real associations
between tested markers and clinicopathological variables
yield very strong statistical evidence. Therefore, the tissue
microarray technology is powerful in the discovery of new
markers with associations to subgroups of samples.
In summary, we have constructed a TGCT tissue micro-
array on which we have evaluated the protein expression of
five candidate testicular cancer genes. We found that JUP
was upregulated and MGMT was downregulated upon initi-
ation of ITGCN, and that the upregulation of CCND2, down-
regulation of FHIT, and further downregulation of MGMT
were related to the development of invasive tumors. GRB7 is
upregulated and JUP is downregulated in the transition into
embryonal carcinoma, whether embryonal carcinomas de-
velop directly from ITGCN or through a seminoma stage.
Additionally, MGMT is reexpressed during further differenti-
ation of embryonal carcinomas. Hence, we have demon-
strated that our tissue microarray enables high-throughput
evaluation of TGCTmarkers, and we have utilized this tool to
validate five TGCT candidate genes whose protein expres-
sions were indeed deregulated.
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